Division of Hematology and Oncology Archives
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
Breast cancer biomarkers of response
Jun. 16, 2022—Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
Biltibo receives career development award to support hematology research
Apr. 21, 2022—Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.
Berlin named interim leader of Hematology and Oncology
Mar. 24, 2022—Jordan Berlin, MD, has been appointed interim leader of Vanderbilt's Division of Hematology and Oncology in the Department of Medicine.
Park named director of Vanderbilt-Ingram Cancer Center
Feb. 17, 2022—Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.
Grant to support Haake’s research on kidney cancer
Feb. 17, 2022—Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt's Scott Haake, MD.
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
Dec. 24, 2021—New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
New Clinician Spotlight: Katherine Walsh
Dec. 21, 2021—Katherine Walsh, MD, has joined Vanderbilt University Medical Center as associate professor of Medicine in the Division of Hematology and Oncology.
Cell signaling targets in leukemia
Dec. 9, 2021—Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.
Shifts in neuroendocrine cancer clinical trial design
Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center
Aug. 19, 2021—Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
